VYNE Therapeutics 향후 성장

Future 기준 점검 0/6

VYNE Therapeutics 의 수익은 연간 15.6% 감소할 것으로 예상되는 반면, 연간 수익은 64.5% 로 증가할 것으로 예상됩니다. EPS는 연간 7.9% 만큼 쇠퇴할 것으로 예상됩니다.

핵심 정보

-15.6%

이익 성장률

-7.90%

EPS 성장률

Pharmaceuticals 이익 성장	14.4%
매출 성장률	64.5%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	08 May 2026

최근 향후 성장 업데이트

Recent updates

분석 기사 • Jun 27

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics press release (NASDAQ:VYNE): Q2 Non-GAAP EPS of -$0.13 beats by $0.02. Revenue of $0.13M (-55.2% Y/Y) beats by $0.03M. As of June 30, 2022, VYNE had cash and cash equivalents of $42.8 million. Shares -4% PM.

분석 기사 • Jul 02

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

분석 기사 • Mar 19

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Jan 13

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Sales of Vyne Therapeutic's minocycline products were just $4 million last quarter which may hamper the company’s ability to sell or license the franchise. Vyne has shifted its focus from marketing the approved minocycline products to 3 pre-clinical assets which require substantial cash and expose investors to a high degree of clinical risk. The largest institutional shareholder has sold most of their position. The cash position is sufficient only through Q2 of 2022 and significant dilution is likely.

분석 기사 • Dec 03

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

분석 기사 • Aug 13

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Market forces rained on the parade of VYNE Therapeutics Inc. ( NASDAQ:VYNE ) shareholders today, when the analysts...

Seeking Alpha • Jun 30

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

VYNE stock has depreciated by 65% in the last 3 months. There are no overwhelmingly critical factors behind this. The market, and smart money, just seem to dislike the stock.

이익 및 매출 성장 예측

NasdaqCM:VYNE - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	7	-88	-121	N/A	2
12/31/2027	N/A	-66	-81	N/A	2
12/31/2026	N/A	-50	-56	N/A	2
3/31/2026	0	-22	-26	-26	N/A
12/31/2025	1	-27	-33	-33	N/A
9/30/2025	1	-34	-38	-38	N/A
6/30/2025	0	-39	-40	-40	N/A
3/31/2025	1	-42	-38	-37	N/A
12/31/2024	1	-40	-34	-34	N/A
9/30/2024	0	-34	-30	-30	N/A
6/30/2024	0	-28	-27	-27	N/A
3/31/2024	0	-29	-28	-28	N/A
12/31/2023	0	-28	-25	-25	N/A
9/30/2023	0	-29	-25	-25	N/A
6/30/2023	0	-33	-27	-27	N/A
3/31/2023	0	-31	-26	-26	N/A
12/31/2022	0	-34	-29	-29	N/A
9/30/2022	1	-35	-34	-34	N/A
6/30/2022	1	-40	-45	-45	N/A
3/31/2022	1	-42	-53	-53	N/A
12/31/2021	1	-44	-56	-56	N/A
9/30/2021	5	-59	-72	-72	N/A
6/30/2021	8	-69	-78	-78	N/A
3/31/2021	19	-226	-97	-97	N/A
12/31/2020	21	-256	-137	-137	N/A
9/30/2020	17	-270	-134	-134	N/A
6/30/2020	14	-269	-133	-132	N/A
3/31/2020	2	-120	-110	-109	N/A
12/31/2019	0	-95	N/A	-73	N/A
9/30/2019	1	-71	N/A	-62	N/A
6/30/2019	2	-64	N/A	-62	N/A
3/31/2019	3	-63	N/A	-62	N/A
12/31/2018	4	-74	N/A	-69	N/A
9/30/2018	4	-77	N/A	-70	N/A
6/30/2018	4	-80	N/A	-69	N/A
3/31/2018	4	-77	N/A	-64	N/A
12/31/2017	4	-66	N/A	-53	N/A
9/30/2017	4	-59	N/A	-53	N/A
6/30/2017	6	-47	N/A	-36	N/A
3/31/2017	6	-39	N/A	-32	N/A
12/31/2016	6	-29	N/A	-27	N/A
9/30/2016	4	-24	N/A	-18	N/A
6/30/2016	2	-21	N/A	-19	N/A
3/31/2016	1	-18	N/A	-18	N/A
12/31/2015	1	-17	N/A	-12	N/A
9/30/2015	4	-11	N/A	-10	N/A
6/30/2015	4	-16	N/A	-7	N/A

애널리스트 향후 성장 전망

수입 대 저축률: VYNE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: VYNE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: VYNE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: VYNE 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 매출: VYNE 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: VYNE의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/21 07:43
종가	2026/05/21 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

VYNE Therapeutics Inc.는 11명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Douglas Tsao	Barclays
Jason Matthew Gerberry	BofA Global Research
Louise Chen	Guggenheim Securities, LLC

VYNE Therapeutics 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates upgraded to US$0.59 loss

Price target decreased by 11% to US$5.50

Consensus EPS estimates fall by 19%

Consensus revenue estimates increase by 250%

Consensus revenue estimates fall by 20%

Consensus EPS estimates fall by 13%

Recent updates

First quarter 2026 earnings released: US$0.084 loss per share (vs US$0.20 loss in 1Q 2025)

VYNE Therapeutics Inc. Receives an Additional 180 Calendar Days Extension to Regain Compliance with the Minimum Bid Price Requirement

Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. (NasdaqCM:VYNE) in a reverse merger transaction.

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2025

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Notice of Non-Compliance with Nasdaq Listing Requirements

Insufficient new directors

First quarter 2025 earnings released: US$0.20 loss per share (vs US$0.15 loss in 1Q 2024)

Consensus EPS estimates upgraded to US$0.59 loss

New major risk - Market cap size

Price target decreased by 11% to US$5.50

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Consensus EPS estimates fall by 19%

VYNE Therapeutics Inc. Provides Program Update on Oral BET inhibitor VYN202

We're A Little Worried About VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Consensus revenue estimates increase by 250%

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

VYNE Therapeutics Provides Update on VYN202 Program

Consensus revenue estimates fall by 20%

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo

VYNE Therapeutics Inc. Therapeutics Reports Positive Top-Line Phase 1A MAD Data for VYN202, Its Novel BD2-Selective Bet Inhibitor

Consensus EPS estimates fall by 13%

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Consensus revenue estimates increase by 50%, EPS downgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202

VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

Consensus EPS estimates upgraded to US$0.81 loss

First quarter 2024 earnings released: US$0.15 loss per share (vs US$1.72 loss in 1Q 2023)

Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo

Consensus EPS estimates upgraded to US$4.82 loss, revenue downgraded

Lead Independent Director recently bought US$51k worth of stock

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors

VYNE Therapeutics Inc., Annual General Meeting, Dec 13, 2023

New major risk - Share price stability

Price target increased by 21% to US$16.50

New major risk - Market cap size

Consensus revenue estimates increase by 60%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

First quarter 2023 earnings released: US$1.72 loss per share (vs US$2.83 loss in 1Q 2022)

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Full year 2022 earnings released

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. announced that it has received $0.3 million in funding

VYNE Therapeutics Inc. Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Consensus revenue estimates increase by 106%

Price target decreased to US$3.50

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.00